CAS 177943-89-4

4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OH, (DISULFIDE BOND) ACETATE

Description:

4,7,10-Tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH, with the CAS number 177943-89-4, is a complex chemical compound characterized by its unique structure that includes a cyclododecan ring, multiple carboxymethyl groups, and a peptide sequence featuring various amino acids. The presence of disulfide bonds indicates that it can form stable linkages between cysteine residues, contributing to its structural integrity and potential biological activity. This compound is likely to exhibit properties such as solubility in polar solvents due to its carboxylic acid groups and may interact with biological systems, making it of interest in fields like medicinal chemistry and biochemistry. Its intricate structure suggests potential applications in drug delivery or as a therapeutic agent, particularly in targeting specific biological pathways. The acetate form indicates that it may be more soluble or stable in certain conditions, enhancing its usability in various chemical and biological applications.

Formula: C₆₅H₉₀N₁₄O₁₉S₂

Synonyms:

• Dota-(Tyr3)-Octreotate Acetate
• Dota-(Tyr3,Thr8)-Octreotide Acetate
• DOTA-[Tyr3]-Octreotate, DOTA-[Tyr3, Thr8]-Octreotide, DOTA-TATE
• N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraaza-cyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-trypto-phyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic(2-7) disulfide

DOTA-(Tyr³)-Octreotate

CAS: 177943-89-4

DOTA-conjugated somatostatin analog for labeling with radiometals such as gallium-67 or gallium-68, indium-111, and yttrium-90. DOTA-TATE is a useful tool in receptor-mediated tumor imaging and peptide receptor-targeted radionuclide therapy. CAS-Number (net): 177943-88-3.

Formula: C₆₅H₉₀N₁₄O₁₉S₂

Purity: 97.5%

Color and Shape: White Powder

Molecular weight: 1435.65

Ref: 01-4046724

DOTATATE acetate

CAS: 177943-89-4

DOTATATE acetate is a DOTA-binding peptide involved in the assessment of functional imaging of highly differentiated neuroendocrine tumors (NETs).

Formula: C₆₀H₉₀N₁₄O₁₉S₂xC₂H₄O₂

Purity: 98.70%

Color and Shape: Solid

Ref: TM-T39193

DOTA-(Tyr3)-Octreotate acetate salt

CAS: 177943-89-4

Formula: C₆₇H₉₄N₁₄O₂₁S₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 1495.6745

Ref: IN-DA0025N0

DOTATATE acetate

CAS: 177943-89-4

DOTATATE acetate

Purity: ≥98%

Ref: 54-BUP00780

DOTA-(Tyr3)-Octreotate acetate salt

Controlled Product

CAS: 177943-89-4

Octreotate is a radiopharmaceutical that is synthesized by reacting DOTA-Tyr3 with octreotide acetate. Octreotate, also known as dotatate, is used in nuclear medicine to treat neuroendocrine tumours. This drug has a high yield and can be reliably prepared using cassettes and computerised equipment to create germanium-68 labelled octreotate. The radionuclide emits positrons and gamma rays, which are used for imaging neuroendocrine tumours in the brain or other organs. Octreotate is a synthetic analogue of the natural hormone octreotide, which binds to receptors on the cell surface and prevents the release of hormones from cells. This may be due to its ability to inhibit protein synthesis by inhibiting rRNA synthesis.

Formula: C₆₅H₉₀N₁₄O₁₉S₂

Purity: Min. 95 Area-%

Color and Shape: White Slightly Yellow Powder

Molecular weight: 1,435.63 g/mol

Ref: 3D-FD109795

DOTA-​(Tyr3)​-​octreotate Acetate Salt

Controlled Product

CAS: 177943-89-4

Stability Hygroscopic
Applications DOTA-​(Tyr3)​-​octreotate can be obtained through preparation of DOTA-containing peptides and radionucleotide complexes as antitumor agents for treating somatostatin postive tumor and metastasized tumors.
References Albert, R., et al.: Jpn. Kokai Tokkyo Koho, JP 08081498 A 19960326 (1996)

Formula: C₆₅H₉₀N₁₄O₁₉S₂·xCH₃COOH

Color and Shape: Neat

Molecular weight: 1435.62 + x(60.05)

Ref: TR-D535760